← Eichor
Condition: Her2 Positive Advanced Solid Tumor Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Her2 Positive Advanced Solid Tumor

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Phase 1 · 40 location(s) · TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) · NCT06625775Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Phase 1/Phase 2 · 13 location(s) · Exscientia AI Ltd., a wholly owned subsidiary of Recursion P · NCT05985655A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Lower Expression Gastrointestinal Canc
Phase 1 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT06500052Anti-HER2 CAR-T Cell Injection in Patients With HER2-positive Advanced Malignant Solid Tumors
NA · 1 location(s) · UTC Therapeutics Inc. · NCT06658951A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
Phase 1 · 4 location(s) · Cogent Biosciences, Inc. · NCT07383506At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Phase 2 · 2 location(s) · Mayo Clinic · NCT05969860BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
Phase 1 · 63 location(s) · BeOne Medicines · NCT06120283HEAT Trial (HER2 Antibody Therapy With Lutetium-177)
EARLY_Phase 1 · 5 location(s) · Radiopharm Theranostics, Ltd · NCT06824155HF50 in HER-2 Positive and Low-expression Advanced Solid Tumors
EARLY_Phase 1 · 1 location(s) · HighField Biopharmaceuticals Corporation · NCT06822998Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Phase 1/Phase 2 · 66 location(s) · Genmab · NCT05579366A Study of BL-M07D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Low Expression Breast Cancer and Other
Phase 1 · 7 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT05461768SPH5030 Tablets in Subjects With Advanced Her2-positive Solid Tumors
EARLY_Phase 1 · 17 location(s) · Shanghai Pharmaceuticals Holding Co., Ltd · NCT05245058A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
Phase 1 · 6 location(s) · Edgewood Oncology Inc. · NCT04872166A Study of AP402 in HER2-Positive Patients With Locally or Advanced Solid Tumors
Phase 1/Phase 2 · 3 location(s) · AP Biosciences Inc. · NCT06669975A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
Phase 1 · 18 location(s) · NiKang Therapeutics, Inc. · NCT07029399HER2 Targeted HypoSti.CAR-T Cells in HER2 Positive Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Chinese PLA General Hospital · NCT05681650IKS014 in Advanced Solid Tumors That Express HER2
Phase 1 · 13 location(s) · Iksuda Therapeutics Ltd. · NCT05872295Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07510802To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer
Phase 2/Phase 3 · 2 location(s) · SUNHO（China）BioPharmaceutical CO., Ltd. · NCT06504732Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Neg
Phase 1 · 1 location(s) · Fred Hutchinson Cancer Center · NCT05098210First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Parti
Phase 1/Phase 2 · 65 location(s) · Eli Lilly and Company · NCT05768139HER-2 B Cell Peptide Vaccine
Phase 1 · 1 location(s) · Pravin T.P Kaumaya · NCT06414733A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Negative Breast Cancer and Other Solid
Phase 1 · 2 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT06503783Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07486089Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor
Phase 1/Phase 2 · 19 location(s) · Yuhan Corporation · NCT05523947A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
Phase 1 · 13 location(s) · Pfizer · NCT07318805Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors
Phase 1 · 1 location(s) · Baylor College of Medicine · NCT03740256A Phase 1/1b Study of IAM1363 in HER2 Cancers
Phase 1 · 53 location(s) · Iambic Therapeutics, Inc · NCT06253871A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-6452 in Adult
Phase 1/Phase 2 · 1 location(s) · Shenzhen Ionova Life Sciences Co., Ltd. · NCT07612891Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
Phase 1/Phase 2 · 17 location(s) · Aminex Therapeutics, Inc. · NCT07287917
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.